紫杉醇脂质体预处理用药方案的安全性研究

目的:探讨上消化道肿瘤用紫杉醇脂质体化疗的几种预处理用药方案的安全性方法:紫杉醇脂质体联合其它化疗药物治疗上消化道肿瘤26例。用紫杉醇脂质体前30min予地塞米松10 mg,静脉注射(i);地塞米松5 mg,静脉注射(ii);甲强龙40 mg,静脉注射(iii);或用紫杉醇脂质体前12 h及2 h口服地塞米松6 mg(i)、4.5 mg(ii)、2.25 mg(iii)。结果:化疗毒副反应主要为Ⅰ～Ⅱ度白细胞减少、贫血、恶心和呕吐,经对症处理后好转。与预处理相关的不良反应包括失眠、血糖升高、乏力、眩晕,无过敏性休克或治疗相关死亡发生。结论:用紫杉醇脂质体前30min予甲强龙40 mg,静脉注射,或用紫杉醇脂质体前12 h及2 h口服地塞米松2.25 mg是较好的预处理用药方案

Safety of Pretreatment Protocols of Paclitaxel Liposome

OBJECTIVE： To evaluate the safety of several pretreatment protocols of paclitaxel liposome as a chemotherapy for upper gastrointestinal tumor. METHODS： 26 patients with upper gastrointestinal tumors receiving paclitaxel liposome in combination with other chemotherapeutics were enrolled. The patients were injected intravenously with dexamethasone 10 mg （i） or dexamethasone 5 rag（ ii ） or prednisolone 40 mg（ iii ） 30 minutes prior administration of paclitaxel liposome, or treated with oral dexamethasone at a dose of 6 mg（ i ）, 4.5 mg（ ii ） or 2.25 mg（ iii ） 12 hours or 2 hours prior administration of paclitaxel liposome. RESULTS： Chemotherapy - induced toxic adverse reactions manifested as grade Ⅰ -Ⅱ leucopenia, anemia, nausea and vomiting, but recovered after symptomatic treatment. Pretreatment - related adverse reactions manifested as insomnia, hyperglycemia, fatigue and vertigo, but no allergic shock or treatment-related death occurred. CONCLUSION： Intravenous injection of prednisolone 40 mg 30 minutes prior administration of paclitaxel liposome or oral administration of dexamethasone 2.25 mg 12 hours and 2 hours prior administration of paclitaxel liposome are preferable pretreatment methods of paclitaxel liposome.